Vericel Corp. (VCEL)
40.19
-0.28
(-0.69%)
USD |
NASDAQ |
Sep 04, 16:00
40.19
0.00 (0.00%)
After-Hours: 20:00
Vericel Research and Development Expense (Quarterly) : 7.493M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 7.493M |
| March 31, 2026 | 8.104M |
| December 31, 2025 | 7.253M |
| September 30, 2025 | 6.318M |
| June 30, 2025 | 6.731M |
| March 31, 2025 | 7.261M |
| December 31, 2024 | 4.923M |
| September 30, 2024 | 6.093M |
| June 30, 2024 | 7.363M |
| March 31, 2024 | 6.418M |
| December 31, 2023 | 4.901M |
| September 30, 2023 | 5.676M |
| June 30, 2023 | 5.253M |
| March 31, 2023 | 5.212M |
| December 31, 2022 | 5.245M |
| September 30, 2022 | 5.046M |
| June 30, 2022 | 4.792M |
| March 31, 2022 | 4.86M |
| December 31, 2021 | 3.924M |
| September 30, 2021 | 4.284M |
| June 30, 2021 | 4.449M |
| March 31, 2021 | 3.63M |
| December 31, 2020 | 3.118M |
| September 30, 2020 | 2.913M |
| June 30, 2020 | 3.226M |
| Date | Value |
|---|---|
| March 31, 2020 | 3.763M |
| December 31, 2019 | 3.217M |
| September 30, 2019 | 3.096M |
| June 30, 2019 | 21.07M |
| March 31, 2019 | 3.008M |
| December 31, 2018 | 3.018M |
| September 30, 2018 | 3.113M |
| June 30, 2018 | 3.739M |
| March 31, 2018 | 3.729M |
| December 31, 2017 | 3.587M |
| September 30, 2017 | 2.919M |
| June 30, 2017 | 2.971M |
| March 31, 2017 | 3.467M |
| December 31, 2016 | 4.258M |
| September 30, 2016 | 3.443M |
| June 30, 2016 | 4.058M |
| March 31, 2016 | 3.536M |
| December 31, 2015 | 7.404M |
| September 30, 2015 | 3.74M |
| June 30, 2015 | 3.369M |
| March 31, 2015 | 4.377M |
| December 31, 2014 | 5.794M |
| September 30, 2014 | 7.835M |
| June 30, 2014 | 4.364M |
| March 31, 2014 | 3.271M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| AbbVie, Inc. | 2.344B |
| ADMA Biologics, Inc. | 6.014M |
| Kyntra Bio, Inc. | 6.821M |
| Conexeu Sciences, Inc. | 0.1523M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |